Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Two year interim analysis of thyroid abnormalities in a trial of alemtuzumab vs high-dose interferon-beta-1a, for treatment of relapsing-remitting multiple sclerosis

Two year interim analysis of thyroid abnormalities in a trial of alemtuzumab vs high-dose interferon-beta-1a, for treatment of relapsing-remitting multiple sclerosis. Multiple Sclerosis. 2006; 12(Supplement 1 (Late Breaking)):P799.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.